Skip to main content

Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership

Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced the expansion of its European operations, including the establishment of its European Union headquarters at Switzerland Innovation Park Basel Area, and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224669284/en/

Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe

Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe

Switzerland Innovation Park Basel Area is part of Switzerland’s national innovation network and located within the Basel region’s globally recognized life sciences cluster, bringing together biopharma companies, research institutions, and clinical innovation leaders.

“Europe is a critical pillar of Clinilabs’ long-term growth strategy,” said Gary K. Zammit, Ph.D., president and chief executive officer of Clinilabs. “Establishing our EU headquarters positions us within one of the world’s most concentrated life sciences ecosystems. Combined with Dr. Nagy’s leadership, this expansion enhances our ability to serve European sponsors with senior-level engagement and localized leadership, increasing our ability to support European clinical programs and meet regional regulatory requirements.”

Dr. Nagy brings more than 25 years of global experience in clinical drug development, operational strategy, and P&L leadership across pharmaceutical and CRO organizations. She will lead Clinilabs’ European growth strategy, oversee EU financial performance, and direct cross-functional teams to deliver operational excellence and sustainable profitability.

“I am excited to lead Clinilabs’ European organization during this important phase of growth,” said Dr. Nagy. “The choice for our EU headquarters positions Clinilabs at the center of a highly collaborative and scientifically advanced environment. I look forward to expanding our European footprint and delivering exceptional value to our clients.”

The European expansion supports Clinilabs’ global strategy to scale its CNS-focused capabilities while maintaining its niche, high-touch operating model. Additional investments will be announced in the coming months.

About Clinilabs

Clinilabs is a global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug, device, and technology development. Drawing on deep, indication-level expertise, a proven process, the latest technology, and global reach spanning North America, the EU, and beyond, Clinilabs expertly manages Phase 1-3 trials to accelerate treatments for a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS disorders.

Clinilabs announces its European Union headquarters at Switzerland Innovation Park Basel Area and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe.

Contacts

Media Contact
Jeanine M. Falinski, MBA
Chief Commercial Officer, Clinilabs
jfalinski@clinilabs.com
+1 (646) 215‑6454

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.45
+4.18 (2.04%)
AAPL  272.12
+5.94 (2.23%)
AMD  215.17
+18.57 (9.45%)
BAC  50.38
-0.70 (-1.36%)
GOOG  312.13
+0.44 (0.14%)
META  639.92
+2.67 (0.42%)
MSFT  386.08
+1.61 (0.42%)
NVDA  193.38
+1.82 (0.95%)
ORCL  144.94
+3.63 (2.57%)
TSLA  404.92
+5.09 (1.27%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.